Ran Nussbaum insider trades: Keros Therapeutics (KROS) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Ran reports to the SEC
and 1 more company
Open-market buys and sales
17 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Oct 15, 2025 | KROS | ↓ Sell | 2,284,612 | $17.75 | $40.6M | By Pontifax (Israel) IV, L.P. | Oct 17, 2025 (2d) |
| Oct 15, 2025 | KROS | ↓ Sell | 1,226,412 | $17.75 | $21.8M | By Pontifax (China) IV, L.P. | Oct 17, 2025 (2d) |
| Oct 15, 2025 | KROS | ↓ Sell | 1,121,045 | $17.75 | $19.9M | By Pontifax (Cayman) IV, L.P. | Oct 17, 2025 (2d) |
| Oct 15, 2025 | KROS | ↓ Sell | 155,262 | $17.75 | $2.8M | By Pontifax Late Stage Fund, L.P. | Oct 17, 2025 (2d) |
| Sep 12, 2025 | LBRX | ↑ Buy | 1,000,000 | $15.00 | $15.0M | Indirect | Sep 16, 2025 (4d) |
| May 13, 2021 | ELOX | ↑ Buy | 5,925,925 | $1.35 | $8.0M | By Pontifax Investment Fund | May 17, 2021 (4d) |
| Nov 17, 2020 | KROS | ↑ Buy | 60,000 | $50.00 | $3.0M | Indirect | Nov 19, 2020 (2d) |
| Apr 13, 2020 | KROS | ↑ Buy | 437,499 | $16.00 | $7.0M | Indirect | Apr 13, 2020 (0d) |
| Jun 27, 2019 | ARQL | ↑ Buy | 307,692 | $9.75 | $3.0M | By Pontifax Fund | Jul 1, 2019 (4d) |
| Jun 24, 2019 | ELOX | ↑ Buy | 200,000 | $9.00 | $1.8M | By Pontifax Investment Fund | Jun 26, 2019 (2d) |
| Jul 13, 2018 | ARQL | ↑ Buy | 181,818 | $5.50 | $1000K | By Pontifax Fund | Oct 22, 2018 (101d) |
| May 18, 2018 | ARQL | ↑ Buy | 8,611 | $3.29 | $28K | Direct | May 18, 2018 (0d) |
| Apr 30, 2018 | ELOX | ↑ Buy | 350,000 | $9.75 | $3.4M | By Pontifax Investment Fund | May 1, 2018 (1d) |
| Mar 22, 2018 | ELOX | ↑ Buy | 12,600 | $7.76 | $98K | By Pontifax Investment Fund | Mar 23, 2018 (1d) |
| May 9, 2017 | KITE | ↑ Buy | 9,832 | $69.11 | $679K | Indirect | May 11, 2017 (2d) |
| Jun 2, 2015 | KITE | ↓ Sell | 305,434 | $55.35 | $16.9M | Indirect | Jun 3, 2015 (1d) |
| Mar 30, 2015 | KITE | ↓ Sell | 193,730 | $60.45 | $11.7M | Indirect | Mar 31, 2015 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other KROS insiders
Open-market trades in the last 12 months
About Ran Nussbaum's insider trades
Ran Nussbaum is a director at Keros Therapeutics (KROS). Since Mar 30, 2015, Ran has reported 11 open-market purchases worth $43.0M and 6 sales worth $113.6M on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (22 filings), option exercises (8 filings), conversions (3 filings), other transactions (3 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every KROS insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.